{"id":6171,"date":"2014-04-15T16:44:16","date_gmt":"2014-04-15T15:44:16","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=6171"},"modified":"2014-04-15T16:44:16","modified_gmt":"2014-04-15T15:44:16","slug":"insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/","title":{"rendered":"L&#8217;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014)"},"content":{"rendered":"<p><strong><a href=\"http:\/\/cofb.org\/c\/document_library\/get_file?uuid=f73bca3d-a5c5-4ccb-8ef0-a53002defc83&amp;groupId=10136\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignright  wp-image-6182\" alt=\"Sin t\u00edtulo\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/04\/Sin-t\u00edtulo1.jpg\" width=\"199\" height=\"263\" \/><\/a><\/strong>Ja podeu llegir el\u00a0<span style=\"text-decoration: underline;\"><strong><a href=\"http:\/\/cofb.org\/c\/document_library\/get_file?uuid=f73bca3d-a5c5-4ccb-8ef0-a53002defc83&amp;groupId=10136\" target=\"_blank\" rel=\"noopener\">nou n\u00famero de la revista cient\u00edfica del\u00a0<\/a><\/strong><a href=\"http:\/\/cofb.org\/c\/document_library\/get_file?uuid=f73bca3d-a5c5-4ccb-8ef0-a53002defc83&amp;groupId=10136\" target=\"_blank\" rel=\"noopener\"><strong>Col\u00b7legi <em>Circular\u00a0<\/em><\/strong><\/a><strong><em><a href=\"http:\/\/cofb.org\/c\/document_library\/get_file?uuid=f73bca3d-a5c5-4ccb-8ef0-a53002defc83&amp;groupId=10136\" target=\"_blank\" rel=\"noopener\">Farmac\u00e8utica<\/a><\/em><\/strong><\/span>, corresponent al primer trimestre de 2014. Aquest cop destaca, entre d&#8217;altres, un article de l&#8217;\u00e0mbit de la Salut P\u00fablica sobre el xarampi\u00f3, l&#8217;objectiu de l&#8217;OMS d&#8217;eliminar-lo a Europa l&#8217;any 2015 i la situaci\u00f3 a Catalunya en relaci\u00f3 a la malaltia.<\/p>\n<p>Com \u00e9s habitual, s&#8217;inclouen articles sobre farmacoter\u00e0pia, casos cl\u00ednics i altres continguts relacionats amb els diferents \u00e0mbits de la farm\u00e0cia. Dins de l&#8217;apartat &#8220;Doc\u00e8ncia&#8221;, un article tracta de l\u2019informe Almagro, elaborat per un grup de farmac\u00e8utics fa 30 anys sobre la situaci\u00f3 de la professi\u00f3. Quins problemes van detectar? Quins camins de futur van marcar llavors? Ho podreu llegir a la Circular.<\/p>\n<p>Us detallem els continguts d&#8217;aquest n\u00famero de la revista a continuaci\u00f3:<\/p>\n<ul>\n<li><strong>Editorial:<\/strong> T. Casas\u00edn<\/li>\n<li><strong>Farmacoter\u00e0pia<\/strong>: Tractament farmacol\u00f2gic de la hiperpl\u00e0sia benigna de pr\u00f2stata<\/li>\n<li><strong>Farmassist\u00e8ncia:<\/strong> Insufici\u00e8ncia renal associada a VIH \/ Gaxilosa en el diagn\u00f2stic d&#8217;hipolact\u00e0sia<\/li>\n<li><strong>Espigolant<\/strong><\/li>\n<li><strong>Casos Cl\u00ednics: <\/strong>S\u00edndrome de Takotsubo associat a tirotoxicosi<\/li>\n<li><strong>Doc\u00e8ncia:<\/strong> L&#8217;informe Almagro 30 anys despr\u00e9s<\/li>\n<li><strong>Alimentaci\u00f3 i Nutrici\u00f3:<\/strong> Passat, present i futur dels complements alimentosos<\/li>\n<li><strong>Salut P\u00fablica:<\/strong> L&#8217;eliminaci\u00f3 del xarampi\u00f3 a Catalunya<\/li>\n<li><strong>Innovadors<\/strong><\/li>\n<li><strong>Vademecum Cultural<\/strong><\/li>\n<\/ul>\n<p>Veure\u00a0<a href=\"http:\/\/www.cofb.org\/web\/guest\/circular-farmaceutica\" target=\"_blank\" rel=\"noopener\">n\u00fameros anteriors de<em>\u00a0Circular Farmac\u00e8utica<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ja podeu llegir el\u00a0nou n\u00famero de la revista cient\u00edfica del\u00a0Col\u00b7legi Circular\u00a0Farmac\u00e8utica, corresponent al primer trimestre de 2014. Aquest cop destaca, entre d&#8217;altres, un article de l&#8217;\u00e0mbit de la Salut P\u00fablica sobre el xarampi\u00f3, l&#8217;objectiu de l&#8217;OMS d&#8217;eliminar-lo a Europa l&#8217;any 2015 i la situaci\u00f3 a Catalunya en relaci\u00f3 a la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6182,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[32],"tags":[2149],"class_list":["post-6171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticies-farmacia","tag-publicacions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L&#039;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Ja podeu llegir el\u00a0nou n\u00famero de la revista cient\u00edfica del\u00a0Col\u00b7legi Circular\u00a0Farmac\u00e8utica, corresponent al primer trimestre de 2014. Aquest cop destaca, entre d&#8217;altres, un article de l&#8217;\u00e0mbit de la Salut P\u00fablica sobre el xarampi\u00f3, l&#8217;objectiu de l&#8217;OMS d&#8217;eliminar-lo a Europa l&#8217;any 2015 i la situaci\u00f3 a Catalunya en relaci\u00f3 a la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-15T15:44:16+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"L&#8217;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014)\",\"datePublished\":\"2014-04-15T15:44:16+00:00\",\"dateModified\":\"2014-04-15T15:44:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Publicacions\"],\"articleSection\":[\"Not\u00edcies farm\u00e0cia\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\",\"name\":\"L'eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2014-04-15T15:44:16+00:00\",\"dateModified\":\"2014-04-15T15:44:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&#8217;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/","og_locale":"ca_ES","og_type":"article","og_title":"L'eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Ja podeu llegir el\u00a0nou n\u00famero de la revista cient\u00edfica del\u00a0Col\u00b7legi Circular\u00a0Farmac\u00e8utica, corresponent al primer trimestre de 2014. Aquest cop destaca, entre d&#8217;altres, un article de l&#8217;\u00e0mbit de la Salut P\u00fablica sobre el xarampi\u00f3, l&#8217;objectiu de l&#8217;OMS d&#8217;eliminar-lo a Europa l&#8217;any 2015 i la situaci\u00f3 a Catalunya en relaci\u00f3 a la [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2014-04-15T15:44:16+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"L&#8217;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014)","datePublished":"2014-04-15T15:44:16+00:00","dateModified":"2014-04-15T15:44:16+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage"},"thumbnailUrl":"","keywords":["Publicacions"],"articleSection":["Not\u00edcies farm\u00e0cia"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/","url":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/","name":"L'eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage"},"thumbnailUrl":"","datePublished":"2014-04-15T15:44:16+00:00","dateModified":"2014-04-15T15:44:16+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2014\/04\/15\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"L&#8217;eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014)"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Ja podeu llegir el\u00a0nou n\u00famero de la revista cient\u00edfica del\u00a0Col\u00b7legi Circular\u00a0Farmac\u00e8utica, corresponent al primer trimestre de 2014. Aquest cop destaca, entre d&#8217;altres, un article de l&#8217;\u00e0mbit de la Salut P\u00fablica sobre el xarampi\u00f3, l&#8217;objectiu de l&#8217;OMS d&#8217;eliminar-lo a Europa l&#8217;any 2015 i la situaci\u00f3 a Catalunya en relaci\u00f3 a la [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/6171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=6171"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/6171\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=6171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=6171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=6171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}